Praxis Precision Medicines Shares Drop After Phase 2/3 Trial of Seizure Drug Fails Primary Endpoint
Praxis Precision Medicines (PRAX) experienced a decline in its stock price during extended trading after announcing that the Phase 2/3 POWER1 trial for vormatrigine, an experimental treatment for focal onset seizures, did not meet its primary endpoint. The failure could impact investor confidence and future development plans.
Tickers: $PRAX